Innovent Shares Promising Phase 1 Results of IBI3003 for Myeloma Patients #China #Suzhou #Multiple_Myeloma #Innovent #IBI3003

Innovent's Jaypirca® Receives Approval in China for CLL Treatment Across All Therapy Lines #China #Suzhou #CLL #Jaypirca #Innovent